|
| | |
|
Am J Psychiatry 1996; 153:417-419
Copyright © 1996 by American Psychiatric Association
Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study
DG Daniel, TE Goldberg, DR Weinberger, JE Kleinman, D Pickar, LJ Lubick and TS Williams
Washington Clinical Research Center, Falls Church, VA 22044, USA.
OBJECTIVE: The purpose of this study was to compare the side effect
+profiles of clozapine and risperidone. METHOD: The subjects were 20
outpatients with schizophrenia or schizoaffective disorder who were
clinically stable on a regimen of clozapine at the time of screening. They
underwent a randomized-order crossover comparison of 6 weeks of risperidone
treatment and 6 weeks of clozapine treatment. Clinical and neurocognitive
variables were assessed by raters blind to medication status, and severity
of side effects was determined from patients' self- reports. RESULTS: Side
effect measures, but not clinical ratings, were significantly different
after 6 weeks of treatment with the two drugs. Patients required more
benztropine for motor effects and complained of more insomnia with
risperidone and more sedation with clozapine. Body weight was higher at the
end of clozapine treatment than at the end of risperidone treatment.
CONCLUSIONS: In this exploratory study, the side effect profiles of
clozapine and risperidone were consistent with the different
pharmacodynamic profiles of the two drugs.
This article has been cited by other articles:
|
|
|
|
 
A. E. Thornton, J. X. Van Snellenberg, A. A. Sepehry, and W. G. Honer
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review
J Psychopharmacol,
May 1, 2006;
20(3):
335 - 346.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
Am J Psychiatry,
February 1, 2006;
163(2):
185 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Honey, E. Pomarol-Clotet, P. R. Corlett, R. A. E. Honey, P. J. Mckenna, E. T. Bullmore, and P. C. Fletcher
Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function
Brain,
November 1, 2005;
128(11):
2597 - 2611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Bilder, R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. McEvoy, M. Kunz, et al.
Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder
Am J Psychiatry,
June 1, 2002;
159(6):
1018 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Harvey and R. S.E. Keefe
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Am J Psychiatry,
February 1, 2001;
158(2):
176 - 184.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. M. Gold, C. Queern, V. N. Iannone, and R. W. Buchanan
Repeatable Battery for the Assessment of Neuropsychological Status as a Screening Test in Schizophrenia, I: Sensitivity, Reliability, and Validity
Am J Psychiatry,
December 1, 1999;
156(12):
1944 - 1950.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. I. Rosebush and M. F. Mazurek
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
Neurology,
March 1, 1999;
52(4):
782 - 782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Galletly, C. R. Clark, A. C. McFarlane, and D. L. Weber
Effects of Clozapine for Non-Treatment-Resistant Patients With Schizophrenia
Psychiatr Serv,
January 1, 1999;
50(1):
101 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lidow and P. S. Goldman-Rakic
Differential Regulation of D2 and D4 Dopamine Receptor mRNAs in the Primate Cerebral Cortex vs. Neostriatum: Effects of Chronic Treatment with Typical and Atypical Antipsychotic Drugs
J. Pharmacol. Exp. Ther.,
November 1, 1997;
283(2):
939 - 946.
[Abstract]
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1996
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
